Irish Journal of Medical Science

, Volume 163, Issue 10, pp 461–463 | Cite as

Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour

  • M. P. MacManus
  • R. J. Harte
  • S. Stranex


A 58 years old man presented with a bulky renal primary tumour, paratracheallymphadenopathy and multiple pulmonary metastases. Spontaneous regression of intrathoracic metastases occurred after low dose palliative irradiation of the primary tumour. Serum levels of Interleukin-2 receptor were elevated during the period of tumour regression but concentrations of other cytokines were normal. Progressive abdominal disease eventually caused death. Autopsy confirmed the presence of renal cell carcinoma with intrathoracic metastases.


Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Renal Carcinoma Spontaneous Regression Palliative Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Everson, T. C., Cole, W. M. Spontaneous Regression of Cancer. Philadelphia: W.B. Saunders, 1966: 11–87.Google Scholar
  2. 2.
    Bloom, H. J. G. Hormone induced and spontaneous regression of metastatic cancer. Cancer 1983: 32, 1066–1071.CrossRefGoogle Scholar
  3. 3.
    Montie, J. E., Stewart, B. H., Straffon, R. A. et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. 1977: 117, 272–275.PubMedGoogle Scholar
  4. 4.
    Muss, H. B. Renal cell carcinoma. In: DeVita, V. T., Hellman, S., Rosenberg, S. A. eds. Biologic therapy of cancer. Philadelphia: J. B. Lippincott Co., 1991: 298–311.Google Scholar
  5. 5.
    West, W. H. Continuous infusion recombinant interleukin2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treatment Reviews 1989: 16 (suppl. A), 83–89.PubMedCrossRefGoogle Scholar
  6. 6.
    Neidhart, J. A. Interferon therapy for the treatment of renal cancer. Cancer 1986: 57, 1696–1699.PubMedCrossRefGoogle Scholar
  7. 7.
    Atzpodien, J., Korfer, A., Franks, C. et al. Home therapy with recombinant interleukin-2 and interferon alpha2b in advanced human malignancies. Lancet 1990: 335, 1509–1512.PubMedCrossRefGoogle Scholar
  8. 8.
    Fairlamb, D. J. Spontaneous regression of metastases of renal cancer. A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981: 47, 2101–2106.CrossRefGoogle Scholar
  9. 9.
    Kjaer, M. The role of medroxyprogesterone acetate (MPA) in the treatment of advanced renal adenocarcinoma. Cancer Treatment Reviews 1988: 15, 195–209.PubMedCrossRefGoogle Scholar
  10. 10.
    Marcus, S. G., Choyke, P. L., Reiter, R. et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 1993: 150, 463–6.PubMedGoogle Scholar
  11. 11.
    Pansera, F. Regression in renal cell carcinoma as re-expression of cell death in kidney development. Perspectives in Biology & Medicine 1992: 426–21.Google Scholar
  12. 12.
    Creaven, P. J., Brenner, D. E., Cowens, J. W. et al. A Phase I clinical trial of recombinant tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol. 1989: 23, 186–191.PubMedGoogle Scholar
  13. 13.
    Bartsh, H. H., Pfizenmaier, K., Schroeder, M. et al. Intralesional application of human tumour necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Clin. Oncol. 1989: 25, 287–291.CrossRefGoogle Scholar
  14. 14.
    Goustin, A. S., Leof, E. B., Shipley, G. D. et al. Growth factors and cancer. Cancer Res. 1986: 46, 1015–1029.PubMedGoogle Scholar
  15. 15.
    Socher, S. H., Martinez, D., Craig, J. B. et al. Tumor Necrosis Factor not detectable in patients with clinical cancer cachexia. J. Natl. Cancer Inst. 1988: 80, 595–598.PubMedCrossRefGoogle Scholar
  16. 16.
    Cotran, R. S., Kumar, V., Robbins, S. I. Robbins. Pathologic Basis of Disease, 4th ed. Philadelphia: W. B. Saunders; 1989: 686.Google Scholar
  17. 17.
    Lissoni, P., Rescaldani, R., Rovelli, F. et al. Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours. Brit. J. Cancer 1989; 60: 616–617.PubMedGoogle Scholar

Copyright information

© Springer 1994

Authors and Affiliations

  • M. P. MacManus
    • 1
  • R. J. Harte
    • 1
  • S. Stranex
    • 1
  1. 1.Northern Ireland Centre for Clinical OncologyBelvoir Park HospitalBelfastNorthern Ireland

Personalised recommendations